Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2

Status

Recruiting 6Active not recruiting 6Not yet recruiting 2Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 31Thoracic 6Genitourinary 6Head & Neck 4CNS 4Gynecologic 3Gastrointestinal 3Tumor-Agnostic 1Other solid neoplasm 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Small Cell Lung Carcinoma 1Lung Diseases 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Brain Neoplasms 1

Interventions

Carboplatin 181pembrolizumab 156Pemetrexed 129Cisplatin 97Drug Therapy 67Paclitaxel 59osimertinib 56Magnetic Resonance Spectroscopy 50durvalumab 49Specimen Handling 49Radiotherapy 49Nivolumab 49atezolizumab 43Docetaxel 43Etoposide 40Bevacizumab 39Blood Specimen Collection 33tislelizumab 31Radiosurgery 31Gemcitabine 29130-nm albumin-bound paclitaxel 27Immunotherapy 25Immune Checkpoint Inhibitors 25cemiplimab 23Injections 23aflutinib 20Cetuximab 18Biopsy 18Standard of Care 17Platinum Compounds 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × sacituzumab govitecan × Thoracic × Clear all
NCT06801834 2026-05-20

EVOKE-SCLC-04

Gilead Sciences

Phase 3 Recruiting
695 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT06431633 2026-05-18

ARIAN

Fundación GECP

Phase 3 Recruiting
129 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT07339059 2026-04-23

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Henry Ford Health System

Phase 2 Recruiting
35 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06055465 2025-05-15

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Chinese University of Hong Kong

Phase 2 Recruiting
37 enrolled
Thoracic

Lung Neoplasms

NCT06401824 2025-05-06

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Maastricht University Medical Center

Phase 2 Recruiting
25 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06667167 2025-01-17

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

Shaare Zedek Medical Center

Phase 2 Recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡